DESCRIPTION: WELLBUTRIN SR (bupropion hydrochloride), an antidepressant of the aminoketone class, is chemically unrelated to tricyclic, tetracyclic, selective serotonin re-uptake inhibitor, or other known antidepressant agents. Its structure closely resembles that of diethylpropion; it is related to phenylethylamines. It is designated as (±)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone hydrochloride. The molecular weight is 276.2. The molecular formula is C₁₃H₁₈ClNO•HCl. Bupropion hydrochloride powder is white, crystalline, and highly soluble in water. It has a bitter taste and produces the sensation of local anesthesia on the oral mucosa. The structural formula is:

\[
\begin{align*}
\text{NHC(CH}_3\text{)}_3 \\
\text{COCHCH}_3 \\
\text{Cl} \\
\text{HCl}
\end{align*}
\]

WELLBUTRIN SR Tablets are supplied for oral administration as 100-mg (blue) and 150-mg (purple), film-coated, sustained-release tablets. Each tablet contains the labeled amount of bupropion hydrochloride and the inactive ingredients: carnauba wax, cysteine hydrochloride, hydroxypropyl methylcellulose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, and titanium dioxide and is printed with edible black ink. In addition, the 100-mg tablet contains FD&C Blue No. 1 Lake and polysorbate 80, and the 150-mg tablet contains FD&C Blue No. 2 Lake, FD&C Red No. 40 Lake, and polysorbate 80.

CLINICAL PHARMACOLOGY:

Pharmacodynamics: Bupropion is a relatively weak inhibitor of the neuronal uptake of norepinephrine, serotonin, and dopamine, and does not inhibit monoamine oxidase. While the mechanism of action of bupropion, as with other antidepressants, is unknown, it is presumed that this action is mediated by noradrenergic and/or dopaminergic mechanisms.

Pharmacokinetics: Bupropion is a racemic mixture. The pharmacologic activity and pharmacokinetics of the individual enantiomers have not been studied.

Following oral administration of WELLBUTRIN SR Tablets to healthy volunteers, peak plasma concentrations of bupropion are achieved within 3 hours. Food increased C_max and AUC of bupropion by 11% and 17%, respectively, indicating that there is no clinically significant food effect.

In vitro tests show that bupropion is 84% bound to human plasma proteins at concentrations up to 200 mcg/mL. The extent of protein binding of the hydroxybupropion metabolite is similar to that
for bupropion, whereas the extent of protein binding of the threohydrobupropion metabolite is about half that seen with bupropion.

Following oral administration of 200 mg of $^{14}$C-bupropion in humans, 87% and 10% of the radioactive dose were recovered in the urine and feces, respectively. The fraction of the oral dose of bupropion excreted unchanged was only 0.5%, a finding consistent with the extensive metabolism of bupropion.

The mean elimination half-life (±SD) of bupropion after chronic dosing is 21 (±9) hours, and steady-state plasma concentrations of bupropion are reached within 8 days.

Bupropion is extensively metabolized in humans. Three metabolites have been shown to be active: hydroxybupropion, which is formed via hydroxylation of the tert-butyl group of bupropion, and the amino-alcohol isomers threohydrobupropion and erythrohydrobupropion, which are formed via reduction of the carbonyl group. In vitro findings suggest that cytochrome P450IIB6 (CYP2B6) is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 isoenzymes are not involved in the formation of threohydrobupropion. Oxidation of the bupropion side chain results in the formation of a glycine conjugate of meta-chlorobenzoic acid, which is then excreted as the major urinary metabolite. The potency and toxicity of the metabolites relative to bupropion have not been fully characterized. Nevertheless, they may be clinically important because their plasma concentrations are higher than those of bupropion.

Because bupropion is extensively metabolized, there is the potential for drug-drug interactions, particularly with those agents that are metabolized by the cytochrome P450IIB6 (CYP2B6) isoenzyme. Although bupropion is not metabolized by cytochrome P450IID6 (CYP2D6), there is the potential for drug-drug interactions when bupropion is co-administered with drugs metabolized by this isoenzyme (see PRECAUTIONS: Drug Interactions).

Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 6 hours after administration of WELLBUTRIN SR Tablets. Peak plasma concentrations of hydroxybupropion are approximately 10 times the peak level of the parent drug at steady state. The elimination half-life of hydroxybupropion is approximately 20 (±5) hours, and its AUC at steady state is about 17 times that of bupropion. The times to peak concentrations for the erythrohydrobupropion and threohydrobupropion metabolites are similar to that of the hydroxybupropion metabolite. However, their elimination half-lives are longer, 33 (±10) and 37 (±13) hours, respectively, and steady-state AUCs are 1.5 and 7 times that of bupropion, respectively.

In a study comparing chronic dosing with WELLBUTRIN SR Tablets 150 mg twice daily to the immediate-release formulation of bupropion at 100 mg three times daily, peak plasma concentrations of bupropion at steady state for WELLBUTRIN SR Tablets were approximately 85% of those achieved with the immediate-release formulation. There was equivalence for bupropion AUCs, as well as equivalence for both peak plasma concentration and AUCs for all three of the detectable bupropion metabolites. Thus, at steady state, WELLBUTRIN SR Tablets, given twice daily, and the immediate-release formulation of bupropion, given three times daily, are essentially bioequivalent for both bupropion and the three quantitatively important metabolites.

Bupropion and its metabolites exhibit linear kinetics following chronic administration of 300 to 450 mg/day.

**Population Subgroups**: Factors or conditions altering metabolic capacity (e.g., liver disease, congestive heart failure [CHF], age, concomitant medications, etc.) or elimination may be expected to influence the degree and extent of accumulation of the active metabolites of bupropion. The elimination of the major metabolites of bupropion may be affected by reduced renal or hepatic
function because they are moderately polar compounds and are likely to undergo further metabolism or conjugation in the liver prior to urinary excretion.

**Hepatic:** The disposition of bupropion following a single 200-mg oral dose was compared in eight healthy volunteers and eight weight- and age-matched volunteers with alcoholic liver disease. The half-life of the hydroxybupropion was significantly prolonged in subjects with alcoholic liver disease (32 hours [±41%] versus 21 hours [±23%]). The differences in half-life for bupropion and the other metabolites in the two patient groups were minimal.

**Renal:** The effect of renal disease on the pharmacokinetics of bupropion has not been studied. The elimination of the major metabolites of bupropion may be affected by reduced renal function.

**Left Ventricular Dysfunction:** During a chronic dosing study with bupropion in 14 depressed patients with left ventricular dysfunction (history of CHF or an enlarged heart on x-ray), no apparent effect on the pharmacokinetics of bupropion or its metabolites, compared to healthy normal volunteers, was revealed.

**Age:** The effects of age on the pharmacokinetics of bupropion and its metabolites have not been fully characterized, but an exploration of steady-state bupropion concentrations from several depression efficacy studies involving patients dosed in a range of 300 to 750 mg/day, on a three times daily schedule, revealed no relationship between age (18 to 83 years) and plasma concentration of bupropion. A single-dose pharmacokinetic study demonstrated that the disposition of bupropion and its metabolites in elderly subjects was similar to that of younger subjects. These data suggest there is no prominent effect of age on bupropion concentration; however, another pharmacokinetic study, single and multiple dose, has suggested that the elderly are at increased risk for accumulation of bupropion and its metabolites (see PRECAUTIONS: Geriatric Use).

**Gender:** A single-dose study involving 12 healthy male and 12 healthy female volunteers revealed no sex-related differences in the pharmacokinetic parameters of bupropion.

**Smokers:** The effects of cigarette smoking on the pharmacokinetics of bupropion were studied in 34 healthy male and female volunteers; 17 were chronic cigarette smokers and 17 were nonsmokers. Following oral administration of a single 150-mg dose of bupropion, there was no statistically
significant difference in $C_{\text{max}}$, half-life, $t_{\text{max}}$, AUC, or clearance of bupropion or its active metabolites between smokers and nonsmokers.

**CLINICAL TRIALS:** The efficacy of the immediate-release formulation of bupropion as a treatment for depression was established in two 4-week, placebo-controlled trials in adult inpatients with depression and in one 6-week, placebo-controlled trial in adult outpatients with depression. In the first study, patients were titrated in a bupropion dose range of 300 to 600 mg/day on a three times daily schedule; 78% of patients received maximum doses of 450 mg/day or less. This trial demonstrated the effectiveness of the immediate-release formulation of bupropion on the Hamilton Depression Rating Scale (HDRS) total score, the depressed mood item (item 1) from that scale, and the Clinical Global Impressions (CGI) severity score. A second study included two fixed doses of the immediate-release formulation of bupropion (300 and 450 mg/day) and placebo. This trial demonstrated the effectiveness of the immediate-release formulation of bupropion, but only at the 450-mg/day dose; the results were positive for the HDRS total score and the CGI severity score, but not for HDRS item 1. In the third study, outpatients received 300 mg/day of the immediate-release formulation of bupropion. This study demonstrated the effectiveness of the immediate-release formulation of bupropion on the HDRS total score, HDRS item 1, the Montgomery-Asberg Depression Rating Scale, the CGI severity score, and the CGI improvement score.

Although there are not as yet independent trials demonstrating the antidepressant effectiveness of the sustained-release formulation of bupropion, studies have demonstrated the bioequivalence of the immediate-release and sustained-release forms of bupropion under steady-state conditions, i.e., bupropion sustained-release 150 mg twice daily was shown to be bioequivalent to 100 mg three times daily of the immediate-release formulation of bupropion, with regard to both rate and extent of absorption, for parent drug and metabolites.

In a longer-term study, outpatients meeting DSM-IV criteria for major depressive disorder, recurrent type, who had responded during an 8-week open trial on WELLBUTRIN SR (150 mg twice daily) were randomized to continuation of their same WELLBUTRIN SR dose or placebo, for up to 44 weeks of observation for relapse. Response during the open phase was defined as CGI Improvement score of 1 (very much improved) or 2 (much improved) for each of the final three weeks. Relapse during the double-blind phase was defined as the investigator’s judgement that drug treatment was needed for worsening depressive symptoms. Patients receiving continued WELLBUTRIN SR treatment experienced significantly lower relapse rates over the subsequent 44 weeks compared to those receiving placebo.

**INDICATIONS AND USAGE:** WELLBUTRIN SR is indicated for the treatment of depression.

The efficacy of bupropion in the treatment of depression was established in two 4-week controlled trials of depressed inpatients and in one 6-week controlled trial of depressed outpatients whose diagnoses corresponded most closely to the Major Depression category of the APA Diagnostic and Statistical Manual (DSM) (see CLINICAL PHARMACOLOGY).

A major depressive episode (DSM-IV) implies the presence of 1) depressed mood or 2) loss of interest or pleasure; in addition, at least five of the following symptoms have been present during the same 2-week period and represent a change from previous functioning: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings
of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation.

The efficacy of WELLBUTRIN SR in maintaining an antidepressant response for up to 44 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial (see CLINICAL PHARMACOLOGY). Nevertheless, the physician who elects to use WELLBUTRIN SR for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient.

CONTRAINDICATIONS: WELLBUTRIN SR is contraindicated in patients with a seizure disorder.

WELLBUTRIN SR is contraindicated in patients treated with ZYBAN® (bupropion hydrochloride) Sustained-Release Tablets, or any other medications that contain bupropion because the incidence of seizure is dose dependent.

WELLBUTRIN SR is contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa because of a higher incidence of seizures noted in patients treated for bulimia with the immediate-release formulation of bupropion.

The concurrent administration of WELLBUTRIN SR Tablets and a monoamine oxidase (MAO) inhibitor is contraindicated. At least 14 days should elapse between discontinuation of an MAO inhibitor and initiation of treatment with WELLBUTRIN SR Tablets.

WELLBUTRIN SR is contraindicated in patients who have shown an allergic response to bupropion or the other ingredients that make up WELLBUTRIN SR Tablets.

WARNINGS: Patients should be made aware that WELLBUTRIN SR contains the same active ingredient found in ZYBAN®, used as an aid to smoking cessation treatment, and that WELLBUTRIN SR should not be used in combination with ZYBAN, or any other medications that contain bupropion.

Seizures: Bupropion is associated with a dose-related risk of seizures. The risk of seizures is also related to patient factors, clinical situations, and concomitant medications, which must be considered in selection of patients for therapy with WELLBUTRIN SR.

- **Dose**: At doses of WELLBUTRIN SR up to a dose of 300 mg/day, the incidence of seizure is approximately 0.1% (1/1000) and increases to approximately 0.4% (4/1000) at the maximum recommended dose of 400 mg/day.

  Data for the immediate-release formulation of bupropion revealed a seizure incidence of approximately 0.4% (i.e., 13 of 3200 patients followed prospectively) in patients treated at doses in a range of 300 to 450 mg/day. The 450-mg/day upper limit of this dose range is close to the currently recommended maximum dose of 400 mg/day for WELLBUTRIN SR Tablets. This seizure incidence (0.4%) may exceed that of other marketed antidepressants and WELLBUTRIN SR Tablets up to 300 mg/day by as much as fourfold. This relative risk is only an approximate estimate because no direct comparative studies have been conducted.

  Additional data accumulated for the immediate-release formulation of bupropion suggested that the estimated seizure incidence increases almost tenfold between 450 and 600 mg/day, which is twice the usual adult dose and one and one-half the maximum recommended daily dose (400 mg) of WELLBUTRIN SR Tablets. This disproportionate increase in seizure incidence with dose incrementation calls for caution in dosing.
Data for WELLBUTRIN SR Tablets revealed a seizure incidence of approximately 0.1% (i.e., 3 of 3100 patients followed prospectively) in patients treated at doses in a range of 100 to 300 mg/day. It is not possible to know if the lower seizure incidence observed in this study involving the sustained-release formulation of bupropion resulted from the different formulation or the lower dose used. However, as noted above, the immediate-release and sustained-release formulations are bioequivalent with regard to both rate and extent of absorption during steady state (the most pertinent condition to estimating seizure incidence), since most observed seizures occur under steady-state conditions.

- **Patient factors:** Predisposing factors that may increase the risk of seizure with bupropion use include history of head trauma or prior seizure, central nervous system (CNS) tumor, the presence of severe hepatic cirrhosis, and concomitant medications that lower seizure threshold.

- **Clinical situations:** Circumstances associated with an increased seizure risk include, among others, excessive use of alcohol; abrupt withdrawal from alcohol or other sedatives; addiction to opiates, cocaine, or stimulants; use of over-the-counter stimulants and anorectics; and diabetes treated with oral hypoglycemics or insulin.

- **Concomitant medications:** Many medications (e.g., antipsychotics, antidepressants, theophylline, systemic steroids) and treatment regimens (e.g., abrupt discontinuation of benzodiazepines) are known to lower seizure threshold.

*Recommendations for Reducing the Risk of Seizure:* Retrospective analysis of clinical experience gained during the development of bupropion suggests that the risk of seizure may be minimized if

- the total daily dose of WELLBUTRIN SR Tablets does *not* exceed 400 mg,
- the daily dose is administered twice daily, and
- the rate of incrementation of dose is gradual.
- No single dose should exceed 200 mg to avoid high peak concentrations of bupropion and/or its metabolites.

WELLBUTRIN SR should be administered with extreme caution to patients with a history of seizure, cranial trauma, or other predisposition(s) toward seizure, or patients treated with other agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) or treatment regimens (e.g., abrupt discontinuation of a benzodiazepine) that lower seizure threshold.

**Hepatic Impairment:** WELLBUTRIN SR should be used with extreme caution in patients with severe hepatic cirrhosis. In these patients a reduced frequency and/or dose is required, as peak bupropion levels are substantially increased and accumulation is likely to occur in such patients to a greater extent than usual. The dose should not exceed 100 mg every day or 150 mg every other day in these patients (see CLINICAL PHARMACOLOGY, PRECAUTIONS, and DOSAGE AND ADMINISTRATION).

**Potential for Hepatotoxicity:** In rats receiving large doses of bupropion chronically, there was an increase in incidence of hepatic hyperplastic nodules and hepatocellular hypertrophy. In dogs receiving large doses of bupropion chronically, various histologic changes were seen in the liver, and laboratory tests suggesting mild hepatocellular injury were noted.

**PRECAUTIONS:**
General: *Agitation and Insomnia:* Patients in placebo-controlled trials with WELLBUTRIN SR Tablets experienced agitation, anxiety, and insomnia as shown in Table 1.

<table>
<thead>
<tr>
<th>Adverse Event Term</th>
<th>WELLBUTRIN SR 300 mg/day (n = 376)</th>
<th>WELLBUTRIN SR 400 mg/day (n = 114)</th>
<th>Placebo (n = 385)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agitation</td>
<td>3%</td>
<td>9%</td>
<td>2%</td>
</tr>
<tr>
<td>Anxiety</td>
<td>5%</td>
<td>6%</td>
<td>3%</td>
</tr>
<tr>
<td>Insomnia</td>
<td>11%</td>
<td>16%</td>
<td>6%</td>
</tr>
</tbody>
</table>

In clinical studies, these symptoms were sometimes of sufficient magnitude to require treatment with sedative/hypnotic drugs.

Symptoms were sufficiently severe to require discontinuation of treatment in 1% and 2.6% of patients treated with 300 and 400 mg/day, respectively, of WELLBUTRIN SR Tablets and 0.8% of patients treated with placebo.

*Psychosis, Confusion, and Other Neuropsychiatric Phenomena:* Depressed patients treated with an immediate-release formulation of bupropion or with WELLBUTRIN SR Tablets have been reported to show a variety of neuropsychiatric signs and symptoms, including delusions, hallucinations, psychosis, concentration disturbance, paranoia, and confusion. In some cases, these symptoms abated upon dose reduction and/or withdrawal of treatment.

*Activation of Psychosis and/or Mania:* Antidepressants can precipitate manic episodes in bipolar disorder patients during the depressed phase of their illness and may activate latent psychosis in other susceptible patients. WELLBUTRIN SR is expected to pose similar risks.

*Altered Appetite and Weight:* In placebo-controlled studies, patients experienced weight gain or weight loss as shown in Table 2.

<table>
<thead>
<tr>
<th>Weight Change</th>
<th>WELLBUTRIN SR 300 mg/day (n = 339)</th>
<th>WELLBUTRIN SR 400 mg/day (n = 112)</th>
<th>Placebo (n = 347)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gained &gt;5 lbs</td>
<td>3%</td>
<td>2%</td>
<td>4%</td>
</tr>
<tr>
<td>Lost &gt;5 lbs</td>
<td>14%</td>
<td>19%</td>
<td>6%</td>
</tr>
</tbody>
</table>

In studies conducted with the immediate-release formulation of bupropion, 35% of patients receiving tricyclic antidepressants gained weight, compared to 9% of patients treated with the immediate-release formulation of bupropion. If weight loss is a major presenting sign of a patient’s depressive illness, the anorectic and/or weight-reducing potential of WELLBUTRIN SR Tablets should be considered.

*Suicide:* The possibility of a suicide attempt is inherent in depression and may persist until significant remission occurs. Accordingly, prescriptions for WELLBUTRIN SR Tablets should be written for the smallest number of tablets consistent with good patient management.

*Allergic Reactions:* Anaphylactoid/anaphylactic reactions characterized by symptoms such as pruritus, urticaria, angioedema, and dyspnea requiring medical treatment have been reported in clinical trials with bupropion. In addition, there have been rare spontaneous postmarketing reports.
of erythema multiforme, Stevens-Johnson syndrome, and anaphylactic shock associated with bupropion. A patient should stop taking WELLBUTRIN SR and consult a doctor if experiencing allergic or anaphylactoid/anaphylactic reactions (e.g., skin rash, pruritus, hives, chest pain, edema, and shortness of breath) during treatment.

Arthralgia, myalgia, and fever with rash and other symptoms suggestive of delayed hypersensitivity have been reported in association with bupropion. These symptoms may resemble serum sickness.

**Cardiovascular Effects:** In clinical practice, hypertension, in some cases severe, requiring acute treatment, has been reported in patients receiving bupropion alone and in combination with nicotine replacement therapy. These events have been observed in both patients with and without evidence of preexisting hypertension.

Data from a comparative study of the sustained-release formulation of bupropion (ZYBAN® Sustained-Release Tablets), nicotine transdermal system (NTS), the combination of sustained-release bupropion plus NTS, and placebo as an aid to smoking cessation suggest a higher incidence of treatment-emergent hypertension in patients treated with the combination of sustained-release bupropion and NTS. In this study, 6.1% of patients treated with the combination of sustained-release bupropion and NTS had treatment-emergent hypertension compared to 2.5%, 1.6%, and 3.1% of patients treated with sustained-release bupropion, NTS, and placebo, respectively. The majority of these patients had evidence of preexisting hypertension. Three patients (1.2%) treated with the combination of ZYBAN and NTS and one patient (0.4%) treated with NTS had study medication discontinued due to hypertension compared to none of the patients treated with ZYBAN or placebo. Monitoring of blood pressure is recommended in patients who receive the combination of bupropion and nicotine replacement.

There is no clinical experience establishing the safety of WELLBUTRIN SR Tablets in patients with a recent history of myocardial infarction or unstable heart disease. Therefore, care should be exercised if it is used in these groups. Bupropion was well tolerated in depressed patients who had previously developed orthostatic hypotension while receiving tricyclic antidepressants, and was also generally well tolerated in a group of 36 depressed inpatients with stable congestive heart failure (CHF). However, bupropion was associated with a rise in supine blood pressure in the study of patients with CHF, resulting in discontinuation of treatment in two patients for exacerbation of baseline hypertension.

**Hepatic or Renal Impairment:** Because bupropion hydrochloride and its metabolites are almost completely excreted through the kidney and metabolites are likely to undergo conjugation in the liver prior to urinary excretion, treatment of patients with renal or hepatic impairment should be initiated at reduced dosage as bupropion and its metabolites may accumulate in such patients to a greater extent than usual. The patient should be closely monitored for possible toxic effects of elevated blood and tissue levels of drug and metabolites.
**Information for Patients:** See the tear-off leaflet at the end of this labeling for Information for the Patient.

Patients should be made aware that WELLBUTRIN SR contains the same active ingredient found in ZYBAN, used as an aid to smoking cessation treatment, and that WELLBUTRIN SR should not be used in combination with ZYBAN or any other medications that contain bupropion hydrochloride.

Physicians are advised to discuss the following issues with patients:

As dose is increased during initial titration to doses above 150 mg/day, patients should be instructed to take WELLBUTRIN SR Tablets in two divided doses, preferably with at least 8 hours between successive doses, to minimize the risk of seizures.

Patients should be told that any CNS-active drug like WELLBUTRIN SR Tablets may impair their ability to perform tasks requiring judgment or motor and cognitive skills. Consequently, until they are reasonably certain that WELLBUTRIN SR Tablets do not adversely affect their performance, they should refrain from driving an automobile or operating complex, hazardous machinery.

Patients should be told that the use and cessation of use of alcohol may alter the seizure threshold, and, therefore, that the consumption of alcohol should be minimized, and, if possible, avoided completely.

Patients should be advised to inform their physicians if they are taking or plan to take any prescription or over-the-counter drugs. Concern is warranted because WELLBUTRIN SR Tablets and other drugs may affect each other’s metabolism.

Patients should be advised to notify their physicians if they become pregnant or intend to become pregnant during therapy.

Patients should be advised to swallow WELLBUTRIN SR Tablets whole so that the release rate is not altered. Do not chew, divide, or crush tablets.

**Laboratory Tests:** There are no specific laboratory tests recommended.

**Drug Interactions:** Few systemic data have been collected on the metabolism of WELLBUTRIN SR following concomitant administration with other drugs or, alternatively, the effect of concomitant administration of WELLBUTRIN SR on the metabolism of other drugs.

Because bupropion is extensively metabolized, the coadministration of other drugs may affect its clinical activity. In vitro studies indicate that bupropion is primarily metabolized to hydroxybupropion by the CYP2B6 isoenzyme. Therefore, the potential exists for a drug interaction between WELLBUTRIN SR and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide). The threo- and erythrohydrobupropion metabolite of bupropion does not appear to be produced by the cytochrome P450 isoenzymes. The effects of concomitant administration of cimetidine on the pharmacokinetics of bupropion and its active metabolites were studied in 24 healthy young male volunteers. Following oral administration of two 150-mg WELLBUTRIN SR Tablets with and without 800 mg of cimetidine, the pharmacokinetics of bupropion and hydroxybupropion were unaffected. However, there were 16% and 32% increases in the AUC and C_max, respectively, of the combined moieties of threo- and erythrohydrobupropion.

While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin).
Animal data indicated that bupropion may be an inducer of drug-metabolizing enzymes in humans. In one study, following chronic administration of bupropion, 100 mg three times daily to eight healthy male volunteers for 14 days, there was no evidence of induction of its own metabolism. Nevertheless, there may be the potential for clinically important alterations of blood levels of coadministered drugs.

**Drugs Metabolized By Cytochrome P450IID6 (CYP2D6):** Many drugs, including most antidepressants (SSRIs, many tricyclics), beta-blockers, antiarrhythmics, and antipsychotics are metabolized by the CYP2D6 isoenzyme. Although bupropion is not metabolized by this isoenzyme, bupropion and hydroxybupropion are inhibitors of CYP2D6 isoenzyme in vitro. In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of bupropion given as 150 mg twice daily followed by a single dose of 50 mg desipramine increased the C\text{max}, AUC, and t\text{1/2} of desipramine by an average of approximately two-, five-, and two-fold, respectively. The effect was present for at least 7 days after the last dose of bupropion. Concomitant use of bupropion with other drugs metabolized by CYP2D6 has not been formally studied.

Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication. If bupropion is added to the treatment regimen of a patient already receiving a drug metabolized by CYP2D6, the need to decrease the dose of the original medication should be considered, particularly for those concomitant medications with a narrow therapeutic index.

**MAO Inhibitors:** Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor phenelzine (see CONTRAINDICATIONS).

**Levodopa:** Limited clinical data suggest a higher incidence of adverse experiences in patients receiving concurrent administration of bupropion and levodopa. Administration of WELLBUTRIN SR Tablets to patients receiving levodopa concurrently should be undertaken with caution, using small initial doses and gradual dose increases.

**Drugs That Lower Seizure Threshold:** Concurrent administration of WELLBUTRIN SR Tablets and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) or treatment regimens (e.g., abrupt discontinuation of benzodiazepines) that lower seizure threshold should be undertaken only with extreme caution (see WARNINGS). Low initial dosing and gradual dose increases should be employed.

**Nicotine Transdermal System:** (see PRECAUTIONS: Cardiovascular Effects).

**Carcinogenesis, Mutagenesis, Impairment of Fertility:** Lifetime carcinogenicity studies were performed in rats and mice at doses up to 300 and 150 mg/kg per day, respectively. These doses are approximately seven and two times the maximum recommended human dose (MRHD), respectively, on a mg/m\textsuperscript{2} basis. In the rat study there was an increase in nodular proliferative lesions of the liver at doses of 100 to 300 mg/kg per day (approximately two to seven times the MRHD on a mg/m\textsuperscript{2} basis); lower doses were not tested. The question of whether or not such lesions may be precursors of neoplasms of the liver is currently unresolved. Similar liver lesions were not seen in the mouse study, and no increase in malignant tumors of the liver and other organs was seen in either study.
Bupropion produced a positive response (two to three times control mutation rate) in two of five strains in the Ames bacterial mutagenicity test and an increase in chromosomal aberrations in one of three in vivo rat bone marrow cytogenetic studies.

A fertility study in rats at doses up to 300 mg/kg revealed no evidence of impaired fertility.

**Pregnancy:** **Teratogenic Effects:** Pregnancy Category B. Teratology studies have been performed at doses up to 450 mg/kg in rats, and at doses up to 150 mg/kg in rabbits (approximately 7 to 11 and 7 times the MRHD, respectively, on a mg/m² basis), and have revealed no evidence of harm to the fetus due to bupropion. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

To monitor fetal outcomes of pregnant women exposed to WELLBUTRIN SR, Glaxo Wellcome Inc. maintains a Bupropion Pregnancy Registry. Health care providers are encouraged to register patients by calling (800) 336-2176.

**Labor and Delivery:** The effect of WELLBUTRIN SR Tablets on labor and delivery in humans is unknown.

**Nursing Mothers:** Like many other drugs, bupropion and its metabolites are secreted in human milk. Because of the potential for serious adverse reactions in nursing infants from WELLBUTRIN SR Tablets, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

**Pediatric Use:** The safety and effectiveness of WELLBUTRIN SR Tablets in pediatric patients below 18 years old have not been established. The immediate-release formulation of bupropion was studied in 104 pediatric patients (age range, 6 to 16) in clinical trials of the drug for other indications. Although generally well tolerated, the limited exposure is insufficient to assess the safety of bupropion in pediatric patients.

**Geriatric Use:** Of the approximately 6000 patients who participated in clinical trials with bupropion sustained-release tablets (depression and smoking cessation studies), 275 were 65 and over and 47 were 75 and over. In addition, several hundred patients 65 and over participated in clinical trials using the immediate-release formulation of bupropion (depression studies). No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

A single-dose pharmacokinetic study demonstrated that the disposition of bupropion and its metabolites in elderly subjects was similar to that of younger subjects; however, another pharmacokinetic study, single and multiple dose, has suggested that the elderly are at increased risk for accumulation of bupropion and its metabolites (see CLINICAL PHARMACOLOGY).

Bupropion hydrochloride and its metabolites are almost completely excreted through the kidney and metabolites are likely to undergo conjugation in the liver prior to urinary excretion. The risk of toxic reaction to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see Use in Patients with Systemic Illness).

**ADVERSE REACTIONS:** (See also WARNINGS and PRECAUTIONS).

The information included under the Incidence in Controlled Trials subsection of ADVERSE REACTIONS is based primarily on data from controlled clinical trials with WELLBUTRIN SR Tablets. Information on additional adverse events associated with the sustained-release formulation
of bupropion in smoking cessation trials, as well as the immediate-release formulation of bupropion, is included in a separate section (see Other Events Observed During the Clinical Development and Postmarketing Experience of Bupropion).

**Incidence in Controlled Trials With WELLBUTRIN SR: Adverse Events Associated With Discontinuation of Treatment Among Patients Treated With WELLBUTRIN SR Tablets:** In placebo-controlled clinical trials, 9% and 11% of patients treated with 300 and 400 mg/day, respectively, of WELLBUTRIN SR Tablets and 4% of patients treated with placebo discontinued treatment due to adverse events. The specific adverse events in these trials that led to discontinuation in at least 1% of patients treated with either 300 or 400 mg/day of WELLBUTRIN SR Tablets and at a rate at least twice the placebo rate are listed in Table 3.

<table>
<thead>
<tr>
<th>Adverse Event Term</th>
<th>WELLBUTRIN SR 300 mg/day (n = 376)</th>
<th>WELLBUTRIN SR 400 mg/day (n = 114)</th>
<th>Placebo (n = 385)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rash</td>
<td>2.4%</td>
<td>0.9%</td>
<td>0.0%</td>
</tr>
<tr>
<td>Nausea</td>
<td>0.8%</td>
<td>1.8%</td>
<td>0.3%</td>
</tr>
<tr>
<td>Agitation</td>
<td>0.3%</td>
<td>1.8%</td>
<td>0.3%</td>
</tr>
<tr>
<td>Migraine</td>
<td>0.0%</td>
<td>1.8%</td>
<td>0.3%</td>
</tr>
</tbody>
</table>

**Adverse Events Occurring at an Incidence of 1% or More Among Patients Treated With WELLBUTRIN SR Tablets:** Table 4 enumerates treatment-emergent adverse events that occurred among patients treated with 300 and 400 mg/day of WELLBUTRIN SR Tablets and with placebo in placebo-controlled trials. Events that occurred in either the 300- or 400-mg/day group at an incidence of 1% or more and were more frequent than in the placebo group are included. Reported adverse events were classified using a COSTART-based Dictionary.

Accurate estimates of the incidence of adverse events associated with the use of any drug are difficult to obtain. Estimates are influenced by drug dose, detection technique, setting, physician judgments, etc. The figures cited cannot be used to predict precisely the incidence of untoward events in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical trials. These incidence figures also cannot be compared with those obtained from other clinical studies involving related drug products as each group of drug trials is conducted under a different set of conditions.

Finally, it is important to emphasize that the tabulation does not reflect the relative severity and/or clinical importance of the events. A better perspective on the serious adverse events associated with the use of WELLBUTRIN SR Tablets is provided in the WARNINGS and PRECAUTIONS sections.
## Table 4: Treatment-Emergent Adverse Events in Placebo-Controlled Trials*

<table>
<thead>
<tr>
<th>Body System/Adverse Event</th>
<th>WELLBUTRIN SR 300 mg/day (n = 376)</th>
<th>WELLBUTRIN SR 400 mg/day (n = 114)</th>
<th>Placebo (n = 385)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Body (General)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>26%</td>
<td>25%</td>
<td>23%</td>
</tr>
<tr>
<td>Infection</td>
<td>8%</td>
<td>9%</td>
<td>6%</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>3%</td>
<td>9%</td>
<td>2%</td>
</tr>
<tr>
<td>Asthenia</td>
<td>2%</td>
<td>4%</td>
<td>2%</td>
</tr>
<tr>
<td>Chest pain</td>
<td>3%</td>
<td>4%</td>
<td>1%</td>
</tr>
<tr>
<td>Pain</td>
<td>2%</td>
<td>3%</td>
<td>2%</td>
</tr>
<tr>
<td>Fever</td>
<td>1%</td>
<td>2%</td>
<td>—</td>
</tr>
<tr>
<td><strong>Cardiovascular</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Palpitation</td>
<td>2%</td>
<td>6%</td>
<td>2%</td>
</tr>
<tr>
<td>Flushing</td>
<td>1%</td>
<td>4%</td>
<td>—</td>
</tr>
<tr>
<td>Migraine</td>
<td>1%</td>
<td>4%</td>
<td>1%</td>
</tr>
<tr>
<td>Hot flashes</td>
<td>1%</td>
<td>3%</td>
<td>1%</td>
</tr>
<tr>
<td><strong>Digestive</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dry mouth</td>
<td>17%</td>
<td>24%</td>
<td>7%</td>
</tr>
<tr>
<td>Nausea</td>
<td>13%</td>
<td>18%</td>
<td>8%</td>
</tr>
<tr>
<td>Constipation</td>
<td>10%</td>
<td>5%</td>
<td>7%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>5%</td>
<td>7%</td>
<td>6%</td>
</tr>
<tr>
<td>Anorexia</td>
<td>5%</td>
<td>3%</td>
<td>2%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>4%</td>
<td>2%</td>
<td>2%</td>
</tr>
<tr>
<td>Dysphagia</td>
<td>0%</td>
<td>2%</td>
<td>0%</td>
</tr>
<tr>
<td><strong>Musculoskeletal</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myalgia</td>
<td>2%</td>
<td>6%</td>
<td>3%</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>1%</td>
<td>4%</td>
<td>1%</td>
</tr>
<tr>
<td>Arthritis</td>
<td>0%</td>
<td>2%</td>
<td>0%</td>
</tr>
<tr>
<td>Twitch</td>
<td>1%</td>
<td>2%</td>
<td>—</td>
</tr>
<tr>
<td><strong>Nervous system</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insomnia</td>
<td>11%</td>
<td>16%</td>
<td>6%</td>
</tr>
<tr>
<td>Dizziness</td>
<td>7%</td>
<td>11%</td>
<td>5%</td>
</tr>
<tr>
<td>Agitation</td>
<td>3%</td>
<td>9%</td>
<td>2%</td>
</tr>
<tr>
<td>Anxiety</td>
<td>5%</td>
<td>6%</td>
<td>3%</td>
</tr>
<tr>
<td>Tremor</td>
<td>6%</td>
<td>3%</td>
<td>1%</td>
</tr>
<tr>
<td>Nervousness</td>
<td>5%</td>
<td>3%</td>
<td>3%</td>
</tr>
<tr>
<td>Somnolence</td>
<td>2%</td>
<td>3%</td>
<td>2%</td>
</tr>
<tr>
<td>Irritability</td>
<td>3%</td>
<td>2%</td>
<td>2%</td>
</tr>
<tr>
<td>Memory decreased</td>
<td>—</td>
<td>3%</td>
<td>1%</td>
</tr>
<tr>
<td>Paresthesia</td>
<td>1%</td>
<td>2%</td>
<td>1%</td>
</tr>
<tr>
<td>Central nervous system stimulation</td>
<td>2%</td>
<td>1%</td>
<td>1%</td>
</tr>
</tbody>
</table>
### WELLBUTRIN SR® (bupropion hydrochloride) Sustained-Release Tablets

<table>
<thead>
<tr>
<th>System</th>
<th>Condition</th>
<th>Placebo</th>
<th>300 mg/day</th>
<th>400 mg/day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Respiratory</td>
<td>Pharyngitis</td>
<td>3%</td>
<td>11%</td>
<td>2%</td>
</tr>
<tr>
<td></td>
<td>Sinusitis</td>
<td>3%</td>
<td>1%</td>
<td>2%</td>
</tr>
<tr>
<td></td>
<td>Increased cough</td>
<td>1%</td>
<td>2%</td>
<td>1%</td>
</tr>
<tr>
<td>Skin</td>
<td>Sweating</td>
<td>6%</td>
<td>5%</td>
<td>2%</td>
</tr>
<tr>
<td></td>
<td>Rash</td>
<td>5%</td>
<td>4%</td>
<td>1%</td>
</tr>
<tr>
<td></td>
<td>Pruritus</td>
<td>2%</td>
<td>4%</td>
<td>2%</td>
</tr>
<tr>
<td></td>
<td>Urticaria</td>
<td>2%</td>
<td>1%</td>
<td>0%</td>
</tr>
<tr>
<td>Special senses</td>
<td>Tinnitus</td>
<td>6%</td>
<td>6%</td>
<td>2%</td>
</tr>
<tr>
<td></td>
<td>Taste perversion</td>
<td>2%</td>
<td>4%</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>Amblyopia</td>
<td>3%</td>
<td>2%</td>
<td>2%</td>
</tr>
<tr>
<td>Urogenital</td>
<td>Urinary frequency</td>
<td>2%</td>
<td>5%</td>
<td>2%</td>
</tr>
<tr>
<td></td>
<td>Urinary urgency</td>
<td>—</td>
<td>2%</td>
<td>0%</td>
</tr>
<tr>
<td></td>
<td>Vaginal hemorrhage†</td>
<td>0%</td>
<td>2%</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>Urinary tract</td>
<td>1%</td>
<td>0%</td>
<td>—</td>
</tr>
</tbody>
</table>

* Adverse events that occurred in at least 1% of patients treated with either 300 or 400 mg/day of WELLBUTRIN SR Tablets, but equally or more frequently in the placebo group, were: abnormal dreams, accidental injury, acne, appetite increased, back pain, bronchitis, dysmenorrhea, dyspepsia, flatulence, flu syndrome, hypertension, neck pain, respiratory disorder, rhinitis, and tooth disorder.

† Incidence based on the number of female patients.

— Hyphen denotes adverse events occurring in greater than 0 but less than 0.5% of patients.

**Incidence of Commonly Observed Adverse Events in Controlled Clinical Trials:** Adverse events from Table 4 occurring in at least 5% of patients treated with WELLBUTRIN SR Tablets and at a rate at least twice the placebo rate are listed below for the 300- and 400-mg/day dose groups.

**WELLBUTRIN SR 300 mg/day:** Anorexia, dry mouth, rash, sweating, tinnitus, and tremor.

**WELLBUTRIN SR 400 mg/day:** Abdominal pain, agitation, anxiety, dizziness, dry mouth, insomnia, myalgia, nausea, palpitation, pharyngitis, sweating, tinnitus, and urinary frequency.

**Other Events Observed During the Clinical Development and Postmarketing Experience of Bupropion:** In addition to the adverse events noted above, the following events have been reported in clinical trials and postmarketing experience with the sustained-release formulation of bupropion in depressed patients and in nondepressed smokers, as well as in clinical trials and postmarketing clinical experience with the immediate-release formulation of bupropion.

Adverse events for which frequencies are provided below occurred in clinical trials with the sustained-release formulation of bupropion. The frequencies represent the proportion of patients who experienced a treatment-emergent adverse event on at least one occasion in placebo-controlled studies for depression (n = 987) or smoking cessation (n = 1013), or patients who experienced an adverse event requiring discontinuation of treatment in an open-label surveillance study with WELLBUTRIN SR Tablets (n = 3100). All treatment-emergent adverse events are included except...
WELLBUTRIN SR® (bupropion hydrochloride) Sustained-Release Tablets

those listed in Tables 1 through 4, those events listed in other safety-related sections, those adverse
events subsumed under COSTART terms that are either overly general or excessively specific so as
to be uninformative, those events not reasonably associated with the use of the drug, and those
events that were not serious and occurred in fewer than two patients. Events of major clinical
importance are described in the WARNINGS and PRECAUTIONS sections of the labeling.

Events are further categorized by body system and listed in order of decreasing frequency
according to the following definitions of frequency: Frequent adverse events are defined as those
occurring in at least 1/100 patients. Infrequent adverse events are those occurring in 1/100 to 1/1000
patients, while rare events are those occurring in less than 1/1000 patients.

Adverse events for which frequencies are not provided occurred in clinical trials or
postmarketing experience with bupropion. Only those adverse events not previously listed for
sustained-release bupropion are included. The extent to which these events may be associated with
WELLBUTRIN SR is unknown.

**Body (General):** Infrequent were chills, facial edema, musculoskeletal chest pain, and
photosensitivity. Rare was malaise. Also observed were arthralgia, myalgia, and fever with rash and
other symptoms suggestive of delayed hypersensitivity. These symptoms may resemble serum
sickness (see PRECAUTIONS).

**Cardiovascular:** Infrequent were postural hypotension, stroke, tachycardia, and vasodilation.
Rare was syncope. Also observed were complete atrioventricular block, extrasystoles, hypotension,
hypertension (in some cases severe, see PRECAUTIONS), myocardial infarction, phlebitis, and
pulmonary embolism.

**Digestive:** Infrequent were abnormal liver function, bruxism, gastric reflux, gingivitis, glossitis,
increased salivation, jaundice, mouth ulcers, stomatitis, and thirst. Rare was edema of tongue. Also
observed were colitis, esophagitis, gastrointestinal hemorrhage, gum hemorrhage, hepatitis,
intestinal perforation, liver damage, pancreatitis, and stomach ulcer.

**Endocrine:** Also observed were hyperglycemia, hypoglycemia, and syndrome of inappropriate
antidiuretic hormone.

**Hemic and Lymphatic:** Infrequent was ecchymosis. Also observed were anemia, leukocytosis,
leukopenia, lymphadenopathy, pancytopenia, and thrombocytopenia.

**Metabolic and Nutritional:** Infrequent were edema and peripheral edema. Also observed was
glycosuria.

**Musculoskeletal:** Infrequent were leg cramps. Also observed were muscle
rigidity/fever/rhabdomyolysis and muscle weakness.

**Nervous System:** Infrequent were abnormal coordination, decreased libido, depersonalization,
dysphoria, emotional lability, hostility, hyperkinesia, hypertonia, hypesthesia, suicidal ideation, and
vertigo. Rare were amnesia, ataxia, derealization, and hypomania. Also observed were abnormal
electroencephalogram (EEG), akinesia, aphasia, coma, delirium, dystarthritis, dyskinesia, dystonia,
euphoria, extrapyramidal syndrome, hypokinesia, increased libido, manic reaction, neuralgia,
neuropathy, paranoid reaction, and unmasking tardive dyskinesia.

**Respiratory:** Rare was bronchospasm. Also observed was pneumonia.

**Skin:** Rare was maculopapular rash. Also observed were alopecia, angioedema, exfoliative
dermatitis, and hirsutism.

**Special Senses:** Infrequent were accommodation abnormality and dry eye. Also observed were
deafness, diplopia, and mydriasis.
Urogenital: Infrequent were impotence, polyuria, and prostate disorder. Also observed were abnormal ejaculation, cystitis, dyspareunia, dysuria, gynecomastia, menopause, painful erection, salpingitis, urinary incontinence, urinary retention, and vaginitis.

DRUG ABUSE AND DEPENDENCE:
Controlled Substance Class: Bupropion is not a controlled substance.
Humans: Controlled clinical studies of bupropion conducted in normal volunteers, in subjects with a history of multiple drug abuse, and in depressed patients showed some increase in motor activity and agitation/excitement.

In a population of individuals experienced with drugs of abuse, a single dose of 400 mg of bupropion produced mild amphetamine-like activity as compared to placebo on the Morphine-Benzodrine Subscale of the Addiction Research Center Inventories (ARCI), and a score intermediate between placebo and amphetamine on the Liking Scale of the ARCI. These scales measure general feelings of euphoria and drug desirability.

Findings in clinical trials, however, are not known to reliably predict the abuse potential of drugs. Nonetheless, evidence from single-dose studies does suggest that the recommended daily dosage of bupropion when administered in divided doses is not likely to be especially reinforcing to amphetamine or stimulant abusers. However, higher doses that could not be tested because of the risk of seizure might be modestly attractive to those who abuse stimulant drugs.

Animals: Studies in rodents and primates have shown that bupropion exhibits some pharmacologic actions common to psychostimulants. In rodents, it has been shown to increase locomotor activity, elicit a mild stereotyped behavioral response, and increase rates of responding in several schedule-controlled behavior paradigms. In primate models to assess the positive reinforcing effects of psychoactive drugs, bupropion was self-administered intravenously. In rats, bupropion produced amphetamine-like and cocaine-like discriminative stimulus effects in drug discrimination paradigms used to characterize the subjective effects of psychoactive drugs.

OVERDOSAGE:
Human Overdose Experience: There has been very limited experience with overdosage of WELLBUTRIN SR Tablets; three cases were reported during clinical trials. One patient ingested 3000 mg of WELLBUTRIN SR Tablets and vomited quickly after the overdose; the patient experienced blurred vision and lightheadedness. A second patient ingested a "handful" of WELLBUTRIN SR Tablets and experienced confusion, lethargy, nausea, jitteriness, and seizure. A third patient ingested 3600 mg of WELLBUTRIN SR Tablets and a bottle of wine; the patient experienced nausea, visual hallucinations, and "grogginess." None of the patients experienced further sequelae.

There has been extensive experience with overdosage of the immediate-release formulation of bupropion. Thirteen overdoses occurred during clinical trials. Twelve patients ingested 850 to 4200 mg and recovered without significant sequelae. Another patient who ingested 9000 mg of the immediate-release formulation of bupropion and 300 mg of tranylcypromine experienced a grand mal seizure and recovered without further sequelae.

Since introduction, overdoses of up to 17,500 mg of the immediate-release formulation of bupropion have been reported. Seizure was reported in approximately one third of all cases. Other serious reactions reported with overdoses of the immediate-release formulation of bupropion alone included hallucinations, loss of consciousness, and sinus tachycardia. Fever, muscle rigidity,
rhabdomyolysis, hypotension, stupor, coma, and respiratory failure have been reported when the immediate-release formulation of bupropion was part of multiple drug overdoses.

Although most patients recovered without sequelae, deaths associated with overdoses of the immediate-release formulation of bupropion alone have been reported rarely in patients ingesting massive doses of the drug. Multiple uncontrolled seizures, bradycardia, cardiac failure, and cardiac arrest prior to death were reported in these patients.

**Overdosage Management:** Ensure an adequate airway, oxygenation, and ventilation. Monitor cardiac rhythm and vital signs. EEG monitoring is also recommended for the first 48 hours post-ingestion. General supportive and symptomatic measures are also recommended. Induction of emesis is not recommended. Gastric lavage with a large-bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion or in symptomatic patients.

Activated charcoal should be administered. There is no experience with the use of forced diuresis, dialysis, hemoperfusion, or exchange transfusion in the management of bupropion overdoses. No specific antidotes for bupropion are known.

Due to the dose-related risk of seizures with WELLBUTRIN SR, hospitalization following suspected overdose should be considered. Based on studies in animals, it is recommended that seizures be treated with intravenous benzodiazepine administration and other supportive measures, as appropriate.

In managing overdosage, consider the possibility of multiple drug involvement. The physician should consider contacting a poison control center for additional information on the treatment of any overdose. Telephone numbers for certified poison control centers are listed in the *Physicians’ Desk Reference* (PDR).

**DOSAGE AND ADMINISTRATION:**

**General Dosing Considerations:** It is particularly important to administer WELLBUTRIN SR Tablets in a manner most likely to minimize the risk of seizure (see WARNINGS). Gradual escalation in dosage is also important if agitation, motor restlessness, and insomnia, often seen during the initial days of treatment, are to be minimized. If necessary, these effects may be managed by temporary reduction of dose or the short-term administration of an intermediate to long-acting sedative hypnotic. A sedative hypnotic usually is not required beyond the first week of treatment. Insomnia may also be minimized by avoiding bedtime doses. If distressing, untoward effects supervene, dose escalation should be stopped.

**Initial Treatment:** The usual adult target dose for WELLBUTRIN SR Tablets is 300 mg/day, given as 150 mg twice daily. Dosing with WELLBUTRIN SR Tablets should begin at 150 mg/day given as a single daily dose in the morning. If the 150-mg initial dose is adequately tolerated, an increase to the 300-mg/day target dose, given as 150 mg twice daily, may be made as early as day 4 of dosing. There should be an interval of at least 8 hours between successive doses.

**Increasing the Dosage Above 300 mg/day:** As with other antidepressants, the full antidepressant effect of WELLBUTRIN SR Tablets may not be evident until 4 weeks of treatment or longer. An increase in dosage to the maximum of 400 mg/day, given as 200 mg twice daily, may be considered for patients in whom no clinical improvement is noted after several weeks of treatment at 300 mg/day.

**Maintenance Treatment:** It is generally agreed that acute episodes of depression require several months or longer of sustained pharmacological therapy beyond response to the acute episode. In a
study in which patients with major depressive disorder, recurrent type, who had responded during 8 weeks of acute treatment with WELLBUTRIN SR were assigned randomly to placebo or to the same dose of WELLBUTRIN SR (150 mg twice daily) during 44 weeks of maintenance treatment as they had received during the acute stabilization phase, longer-term efficacy was demonstrated (see CLINICAL TRIALS under CLINICAL PHARMACOLOGY). Based on these limited data, it is unknown whether or not the dose of WELLBUTRIN SR needed for maintenance treatment is identical to the dose needed to achieve an initial response. Patients should be periodically reassessed to determine the need for maintenance treatment and the appropriate dose for such treatment.

HOW SUPPLIED: WELLBUTRIN SR Sustained-Release Tablets, 100 mg of bupropion hydrochloride, are blue, round, biconvex, film-coated tablets printed with “WELLBUTRIN SR 100” in bottles of 60 (NDC 0173-0947-55) tablets.

WELLBUTRIN SR Sustained-Release Tablets, 150 mg of bupropion hydrochloride, are purple, round, biconvex, film-coated tablets printed with "WELLBUTRIN SR 150" in bottles of 60 (NDC 0173-0135-55) tablets.

Store at controlled room temperature, 20° to 25°C (68° to 77°F) [see USP]. Dispense in a tight, light-resistant container as defined in the USP.

GlaxoWellcome
Distributed by:
Glaxo Wellcome Inc.
Research Triangle Park, NC 27709

Manufactured by:
Glaxo Wellcome Inc.
Research Triangle Park, NC 27709
or
Catalytica Pharmaceuticals, Inc.
Greenville, NC 27834

US Patent Nos. 5,358,970; 5,427,798; 5,731,000; 5,763,493; and Re. 33,994

©Copyright 1996, 1998, 1999, 2000, 2001, Glaxo Wellcome Inc. All rights reserved.

March 2001 RL-917
Information for the Patient
WELLBUTRIN SR® (bupropion hydrochloride) Sustained-Release Tablets

Please read this information before you start taking WELLBUTRIN SR. Also read this leaflet each
time you renew your prescription, in case anything has changed. This information is not intended to
take the place of discussions between you and your doctor. You and your doctor should discuss
WELLBUTRIN SR as it relates to the treatment of your depression. Do not let anyone else use your
WELLBUTRIN SR.

IMPORTANT WARNING:
At a dose of 300 mg each day, there is a chance that approximately 1 out of every 1000 people
taking bupropion hydrochloride, the active ingredient in WELLBUTRIN SR, will have a seizure. At
a dose of 400 mg each day, there is a chance that approximately 4 out of every 1000 people will
have a seizure. The chance of this happening increases if you:
• have a seizure disorder (for example, epilepsy);
• have or have had an eating disorder (for example, bulimia or anorexia nervosa);
• take more than the recommended amount of WELLBUTRIN SR; or
• take other medicines with the same active ingredient that is in WELLBUTRIN SR, such as
ZYBAN® (bupropion hydrochloride) Sustained-Release Tablets (used to help people quit
smoking).
You can reduce the chance of experiencing a seizure by following your doctor’s directions on
how to take WELLBUTRIN SR. You should also discuss with your doctor whether WELLBUTRIN
SR is right for you.

1. What is WELLBUTRIN SR?
WELLBUTRIN SR is a prescription medicine used to treat depression.

2. Who should not take WELLBUTRIN SR?
You should not take WELLBUTRIN SR if you:
• have a seizure disorder (for example, epilepsy);
• are already taking ZYBAN or any other medicines that contain bupropion hydrochloride;
• have or have had an eating disorder (for example, bulimia or anorexia nervosa);
• are currently taking or have recently taken a monoamine oxidase inhibitor (MAOI); or
• are allergic to bupropion.

3. Are there special concerns for women?
WELLBUTRIN SR is not recommended for women who are pregnant or breast-feeding. Women
should notify their doctor if they become pregnant or intend to become pregnant while taking
WELLBUTRIN SR.

4. How should I take WELLBUTRIN SR?
WELLBUTRIN SR® (bupropion hydrochloride) Sustained-Release Tablets

- You should take WELLBUTRIN SR as directed by your doctor. The usual recommended dosing is to begin treatment with WELLBUTRIN SR by taking one 150-mg tablet in the morning. As early as day 4 of treatment, your doctor may increase your dose to one 150-mg tablet in the morning and one 150-mg tablet in the early evening (for a total of 300 mg each day).
  
  If your depression does not improve after several weeks, your doctor may increase the dose of WELLBUTRIN SR to a total of 400 mg each day (taken as 200 mg in the morning and 200 mg in the early evening). Doses should be taken at least 8 hours apart.

- **Never take an “extra” dose of WELLBUTRIN SR Tablets for any reason, even if you miss a dose.** If you forget to take a dose, do not take an extra tablet to “catch up” for the dose you forgot. Wait and take your next tablet at the regular time. Do not take more tablets than your doctor prescribed. This is important so you do not increase your chance of having a seizure.

- It is important to swallow WELLBUTRIN SR Tablets whole. Do not chew, divide, or crush tablets.

5. **How long should I take WELLBUTRIN SR?**

   Only you and your doctor can determine how long you should take WELLBUTRIN SR. You and your doctor should discuss your signs and symptoms of depression regularly to determine how long you should take WELLBUTRIN SR. Do not stop taking your medicine or decrease the amount of medicine you are taking without talking to your doctor first.

6. **What are possible side effects of WELLBUTRIN SR?**

   Like all medicines, WELLBUTRIN SR may cause side effects.

   - The most common side effects of WELLBUTRIN SR in clinical studies were:
     
     At 300 mg/day: Loss of appetite, dry mouth, skin rash, sweating, ringing in the ears, and shakiness.
     
     At 400 mg/day: Abdominal (stomach) pain, agitation, anxiety, dizziness, dry mouth, difficulty sleeping, muscle pain, nausea, rapid heart beat, sore throat, sweating, ringing in the ears, and urinating more often.

   - The side effects of WELLBUTRIN SR are generally mild and often disappear after a few weeks. If you have nausea, you may want to take your medicine with food. If you have difficulty sleeping, avoid taking your medicine too close to bedtime.

   - The most common side effects that caused people to stop taking WELLBUTRIN SR during clinical studies were skin rash, nausea, agitation, and migraine (a severe type of headache).

   - Stop taking WELLBUTRIN SR and contact your doctor or health care professional if you have signs of an allergic reaction such as a skin rash, or difficulty in breathing. Discuss any other troublesome side effects with your doctor.

   - Use caution before driving a car or operating complex, hazardous machinery until you know if WELLBUTRIN SR affects your ability to perform these tasks.

7. **Will taking WELLBUTRIN SR change my body weight?**

   In clinical studies with WELLBUTRIN SR, some people lost weight and other people gained weight.

   For people who lost weight, 14 out of 100 people taking 300 mg/day of WELLBUTRIN SR lost more than 5 lbs, 19 out of 100 people taking 400 mg/day lost more than 5 lbs, and 6 out of 100 people taking placebo (a sugar pill) lost more than 5 lbs.

   For people who gained weight, 3 out of 100 people taking 300 mg/day of WELLBUTRIN SR gained more than 5 lbs, 2 out of 100 people taking 400 mg/day gained more than 5 lbs, and 4 out of 100 people taking placebo (a sugar pill) gained more than 5 lbs.
Since weight change (loss or gain) also can be a symptom of depression, you should discuss with your doctor whether WELLBUTRIN SR is right for you.

8. Should I drink alcohol while I am taking WELLBUTRIN SR?
   It is best to not drink alcohol at all or to drink very little while taking WELLBUTRIN SR. If you usually drink a lot of alcohol, or if you drink a lot of alcohol and suddenly stop, you may increase your chance of having a seizure. Therefore, it is important to discuss your use of alcohol with your doctor before you begin taking WELLBUTRIN SR.

9. Will WELLBUTRIN SR affect other medicines I am taking?
   WELLBUTRIN SR may affect other medicines you’re taking. It is important not to take medicines that may increase the chance for you to have a seizure. Therefore, you should make sure that your doctor knows about all medicines—prescription and over-the-counter—you are taking or plan to take.

10. Do WELLBUTRIN SR Tablets have a characteristic odor?
    WELLBUTRIN SR Tablets may have a characteristic odor. If present, this odor is normal.

11. How should I store WELLBUTRIN SR?
    • Store WELLBUTRIN SR at room temperature, out of direct sunlight.
    • Keep WELLBUTRIN SR in a tightly closed container.
    • Keep WELLBUTRIN SR out of the reach of children.

This summary provides important information about WELLBUTRIN SR. This summary cannot replace the more detailed information that you need from your doctor. If you have any questions or concerns about either WELLBUTRIN SR or depression, talk to your doctor or other health care professional.